Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
September 9, 2025
September 8, 2025
07142307-dadf-4c95-927c-469f261c1c58
Related Documents
Classification Categories for Certain Supplements Under BsUFA III
Guidance DocumentSeptember 8, 2025Center for Drug Evaluation and Research
Classification Categories for Certain Supplements Under BsUFA III
Guidance DocumentAugust 11, 2023Center for Drug Evaluation and Research
Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations Guidance for Industry
Guidance DocumentMay 22, 2019Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox